Actuate Therapeutics, Inc. Common stock (ACTU)

Actuate Therapeutics, Inc. Common stock (ACTU) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $14.5M; returns 1 day -7.9%, 1 week -21.5%, 1 year -93.4%.

Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for high-impact, difficult-to-treat cancers. The company's primary focus is on advancing its lead investigational drug, elraglusib, a novel glycogen synthase kinase-3 beta (GSK-3β) inhibitor.

Groups ACTU belongs to

• Biotechnology
• Clinical Stage Biotech
• Oncology
• Cancer Therapeutics
• Clinical Stage
• Healthcare
• Pharmaceuticals
• Biopharmaceutical
• Pancreatic Cancer
• R&D

ACTU financial model: income statement, cash flow and balance sheet